- At PiBi-POP, we start where wellness begins — the gut
- 🇺🇸 Proudly American Owned Small Business
A clinically proven, spore-forming probiotic strain — validated across multiple randomized controlled trials for gut health, IBS relief, and microbiome modulation.
Bacillus Coagulans is a gram-positive, spore-forming, non-pathogenic, non-hemolytic, rod-shaped bacterium — stable across a wide range of pH and temperatures. It produces lactic acid and bacteriocins that prevent the growth of pathogenic microorganisms, and can sustain gastric and bile acids in the human gut, remaining stable even in highly acidic environments.
In silico analysis confirms it is sensitive to 17 classes of antibiotics and has no gene for biogenic amines — making it genetically stable at every stage.
No encapsulation needed
No encapsulation needed
<10% loss at room temp
Scientifically & clinically proven
Clinically Proven Relief from Irritable Bowel Syndrome (IBS) symptoms, including bloating, diarrhea, and abdominal pain.
Displaces gas-producing bacteria and improves fermentation to quiet your gut from the inside out.
Aids in constipation relief and improves gut motility for more consistent, comfortable elimination.
Modulates behavior via the gut-brain axis by measurably increasing serotonin levels.
Replenishes gut microbiota and improves the abundance of beneficial bacteria to restore microbiome diversity (Clinically Proven).
Supports the breakdown of proteins into amino acids and improves nutrient absorption through a strengthened gut lining.
The Study: A randomized, double-blind, placebo-controlled trial involving 100 IBS patients over 84 days at a dose of 2 billion CFU/day.
The Result: Statistically significant reduction in IBS Symptom Severity Score (IBS-SSS) compared to the placebo group by the end of treatment (p < 0.05).
The Study: A 42-day randomized, double-blind, placebo-controlled trial with 48 healthy volunteers at 1 billion CFU/day.
The Result: A measurable increase in the abundance of beneficial bacteria (Bacillota phylum), effectively restoring healthy microbiome diversity.
The Study: In vivo rat model measuring defecation frequency across multiple dose groups.
The Result: Both low and high-dose groups showed significantly reduced defecation frequency compared to disease control (p < 0.05)
The Study: In vivo rat model measuring neurotransmitter levels (serotonin, dopamine, noradrenaline) in the frontal cortex.
The Result: Measurably increased serotonin and dopamine levels compared to disease control—showing effects comparable to standard fluoxetine treatment.
The above health statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before use if pregnant, nursing, under 18, or taking medication.
In-silico analysis of probiotic attributes and safety assessment of probiotic strain Bacillus Coagulans BCP92 for human application. Lett Appl Microbiol.
Food storage, processing and genetic stability studies of Bacillus (Heyndrickxia) Coagulans BCP92 MTCC 25460. Appl Food Biotechnol.
Role of Bacillus Coagulans (Heyndrickxia Coagulans) BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial. Medicine (Baltimore).
Efficacy and safety assessment of probiotic Bacillus Coagulans (Heyndrickxia Coagulans) BCP92 for treatment of diarrhea. Toxicol Res (Camb).
Bacillus Coagulans Enhances Protein Digestion and Absorption Human studies show that Bacillus Coagulans improves protein breakdown into amino acids, promoting better absorption through a strengthened gut lining. This probiotic supports optimal nutrient utilization and overall metabolic health.
In a randomized controlled trial with 30 healthy participants (ages 18–50), 14 were assigned to the test group and 16 to placebo. Over eight weeks, the test group consumed at least 1 billion CFU per day, with mean urine urea nitrogen levels measured at week 4 and week 8. Results indicated higher protein absorption in the Bacillus Coagulans group compared to placebo.
